Rainbow Rare Earths Phalaborwa project shaping up to be one of the lowest cost producers globally. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,398.00
Bid: 12,398.00
Ask: 12,402.00
Change: 58.00 (0.47%)
Spread: 4.00 (0.032%)
Open: 12,414.00
High: 12,414.00
Low: 12,300.00
Prev. Close: 12,340.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UPDATE 2-FTSE 100 leaps to five-month high on vaccine optimism

Wed, 11th Nov 2020 09:31

(For a Reuters live blog on U.S., UK and European stock
markets, click LIVE/ or type LIVE/ in a news window)

* Flutter, BAE Systems jump on raising profit forecast

* Workspace slips on first-half loss, dividend push back

* FTSE 100 up 1.4%, FTSE 250 adds 1.6%
(Updates to close)

By Devik Jain

Nov 11 (Reuters) - London stocks jumped on Wednesday,
logging nearly 8% gains this week, as optimism about an
effective COVID-19 vaccine offset concerns over surging
coronavirus cases and a deadlock in Brexit trade talks with the
European Union.

The blue-chip FTSE 100 index closed up 1.4%,
touching its highest level since June 10, with British Airways
owner IAG rising 8% after Goldman Sachs upgraded the
stock to 'buy'.

A weaker sterling also boosted dollar earners such as
AstraZeneca Plc, British American Tobacco Plc
and Unilever Plc and HSBC Holdings Plc.

The domestically focused mid-cap FTSE 250 ended 1.6%
higher, boosted by financial and real estate
stocks.

"This week's news on a vaccine, while welcome, does not
change the fact that France, Germany and the UK are still in the
middle of partial economic lockdowns," Michael Hewson, chief
market analyst at CMC Markets, wrote in a note.

"However, for now markets appear content to ignore this and
are focusing on the potential green pastures of a post-pandemic
world, with a workable vaccine."

After falling nearly 5% in October, the FTSE 100 is up more
than 14% this month, outperforming its U.S. and European peers
as a slew of stimulus measures and positive vaccine data
supported hopes of a sooner-than-expected economic recovery.

England's Deputy Chief Medical Officer Jonathan Van-Tam said
the country was ready to roll out a vaccine once regulators
approved it as safe, as it grapples with more than 61,000
COVID-related deaths, Europe's highest toll.

Brexit news also drew attention with Prime Minister Boris
Johnson saying he was hopeful a trade deal with the EU could
still be agreed, but that Brussels needed to understand
Britain's priorities.

Workspace Group slipped 2.5%, after it swung to a
first-half loss and deferred a decision on full-year dividend.

Online betting group Flutter Entertainment and
defence company BAE Systems Plc jumped 5% and 2.5%
respectively, after they raised their annual earnings forecast.
(Reporting by Devik Jain in Bengaluru; Editing by Bernard Orr,
Anil D'Silva and Mark Heinrich)

More News
4 Sep 2023 12:13

LONDON MARKET MIDDAY: Hopes of rate peak, China turnaround lift stocks

(Alliance News) - Stock prices in London were higher at midday on Monday, with market mood buoyed by news of stimulus measures in China and increasing optimism for the future of interest rates across the Atlantic.

Read more
4 Sep 2023 08:25

IN BRIEF: Astra drug gets China okay for chronic lymphocytic leukaemia

AstraZeneca PLC - Cambridge-based pharmaceutical maker - Astra's Calquence is approved in China for treatment of chronic lymphocytic leukaemia or small lymphocytic lymphoma in adult patients who have received at least one prior therapy. The National Medical Products Administration approves Calquence, whose generic name is acalabrutinib, based on two different trials, including one in China. Astra notes that CLL is the most prevalent type of adult leukaemia around the world and represents about 6.4% of B-cell non-Hodgkin lymphoma patients in China. Calquence already is approved for treatment of CLL and SLL in the US and Japan and is approved for CLL in the EU.

Read more
4 Sep 2023 07:36

LONDON BRIEFING: CMC names new CFO; takeover offer for Ergomed

(Alliance News) - Stocks in London are expected to open on a positive note on Monday, amid an improvement in global risk sentiment.

Read more
29 Aug 2023 20:24

Blood thinners, diabetes meds among first 10 drugs for US price negotiations

Aug 29(Reuters) - The Biden administration on Tuesday released its list of 10 prescription medicines that will be subject to the first-ever price negotiations by the U.S. Medicare health program that covers 66 million people, with big-selling blood thinner Eliquis from Bristol Myers Squibb and Pfizer among them.

Read more
29 Aug 2023 12:33

US government names first 10 drugs for Medicare price negotiation

Aug 29 (Reuters) - The Biden administration on Tuesday released its list of 10 prescription medicines including blood thinner Eliquis from Bristol Myers Squibb and Pfizer that will be subject to the first-ever price negotiations by the Medicare health program.

Read more
29 Aug 2023 11:00

US to name first 10 drugs for Medicare price negotiation

Aug 29(Reuters) - The Biden administration on Tuesday is expected to release its list of 10 prescription medicines that will be subject to the first-ever price negotiations by the U.S. Medicare health program that covers 66 million people.

Read more
25 Aug 2023 11:59

Novo says Wegovy drug helps obese people with heart failure in trial

Aug 25 (Reuters) - Novo Nordisk said its hugely popular drug Wegovy was shown to substantially ease heart failure in obese people, as the Danish drugmaker seeks to further build its case for the medicine's health benefits beyond weight loss.

Read more
24 Aug 2023 16:24

UPDATE: AstraZeneca, Merck & Co say Lynparza approved in Japan

(Alliance News) - AstraZeneca PLC and Merck & Co Inc on Thursday jointly said its Lynparza treatments have been approved in Japan.

Read more
24 Aug 2023 08:25

AstraZeneca says Soliris and Lynparza approved in Japan

(Alliance News) - AstraZeneca PLC on Thursday said both its Soliris and Lynparza treatments have been approved in Japan.

Read more
23 Aug 2023 16:15

AstraZeneca facing two London lawsuits over COVID-19 vaccines

LONDON, Aug 23 (Reuters) - AstraZeneca is facing two London lawsuits, including one from the husband of a woman who died after receiving the Anglo-Swedish drugmaker's COVID-19 vaccine, in the first of potentially dozens of cases brought in England.

Read more
23 Aug 2023 12:10

LONDON MARKET MIDDAY: Stocks rise but pound slumps on sub-par UK data

(Alliance News) - Stocks in Europe were on the up heading into Wednesday afternoon, with equity markets in a confident mood on the eve of the Jackson Hole central banking event, shaking off tepid economic data which hurt the pound and euro.

Read more
23 Aug 2023 07:42

Daiichi Sankyo and AstraZeneca's Enhertu wins new approval in Japan

(Alliance News) - AstraZeneca PLC's partner Daiichi Sankyo Co Ltd on Wednesday announced that their cancer drug Enhertu has received another approval in Japan.

Read more
22 Aug 2023 06:06

Pay for FTSE 100 bosses jumps 16% as wider wages behind inflation

(Alliance News) - The bosses of Britain's biggest companies saw their pay surge by 16% last year as most workers saw their pay packets outstripped by inflation, according to new research.

Read more
21 Aug 2023 22:37

US FDA approves Pfizer's maternal RSV vaccine to protect infants

Aug 21 (Reuters) - The U.S. Food and Drug Administration on Monday approved Pfizer's respiratory syncytial virus (RSV) vaccine for use in women during the middle of the third trimester of pregnancy to protect their babies.

Read more
21 Aug 2023 20:56

Britain's CEOs get 16% pay rise to 3.9 mln pounds even as workers struggle

LONDON, Aug 21 (Reuters) - The bosses of Britain's biggest companies saw their pay jump 16% in 2022, sending their average earnings to 118 times the median UK full-time worker's while employees struggled with soaring inflation, new research showed on Monday.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.